Skip to main content
SpringerLink
Log in

Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms

  • Pharmacodynamics
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

To compare the effect of esomeprazole 40 mg with lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg on intragastric pH during single and repeated dosing in four separate studies in patients with symptoms of gastro-oesophageal reflux disorder (GERD).

Methods

In four randomised crossover studies, patients with symptoms of GERD received once-daily treatment with esomeprazole 40 mg or lansoprazole 30 mg (study A), omeprazole 20 mg (study B), pantoprazole 40 mg (study C) and rabeprazole 20 mg (study D) for 5 days. Continuous 24-h intragastric pH recording was performed on days 1 (except study B) and 5. Percentage of time over 24 h with intragastric pH greater than 4, 24-h median pH and the proportion of patients with pH greater than 4 for greater than or equal to 12 h and 16 h during the 24-h recording periods were investigated.

Results

In all four studies, esomeprazole 40 mg OD maintained intragastric pH greater than 4 for a significantly higher mean percentage of the 24-h period compared with all other proton pump inhibitors (PPIs) on days 1 (esomeprazole 40.6% versus lansoprazole 33.4%, P=0.0182; esomeprazole 50.3% versus pantoprazole 29.1%, P<0.001; esomeprazole 41.0% versus rabeprazole 29.4%, P=0.002) and 5 (esomeprazole 57.7% versus lansoprazole 44.5%, P<0.0001; esomeprazole 69.8% versus omeprazole 43.7%, P<0.0001; esomeprazole 67.0% versus pantoprazole 44.8%, P<0.001; esomeprazole 59.4% versus rabeprazole 44.5%, P<0.0001). Higher 24-h median pH and a higher proportion of patients with intragastric pH greater than 4 for greater than or equal to 12 h and 16 h were reported with esomeprazole 40 mg OD than with all the other PPIs in each study.

Conclusion

Esomeprazole 40 mg provides greater acid control in more patients and maintains intragastric pH greater than 4 for a longer period than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with symptoms of GERD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1a, b
Fig. 2
Fig. 3a, b

Similar content being viewed by others

References

  1. Bell NJ, Burget D, Howden CW et al (1992) Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 51[Suppl 1]:59–67

    PubMed  Google Scholar 

  2. Joelsson B, Johnsson F (1989) Heartburn—the acid test. Gut 30:1523–1525

    CAS  PubMed  Google Scholar 

  3. Johnson LF, DeMeester TR (1986) Development of the 24-hour intraesophageal pH monitoring composite scoring system. J Clin Gastroenterol 8[Suppl 1]:52–58

    PubMed  Google Scholar 

  4. Hunt RH (1999) Importance of pH control in the management of GERD. Arch Intern Med 159:649–657

    Google Scholar 

  5. Chiba N (1997) Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Can J Gastroenterol 11[Suppl B]:66B–73B

    PubMed  Google Scholar 

  6. Chiba N, De Gara CJ, Wilkinson JM et al (1997) Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 112:1798–1810

    CAS  PubMed  Google Scholar 

  7. Dent J, Brun J, Fendrick AM et al (1999) An evidence-based appraisal of reflux disease management—the Genval workshop report. Gut 44[Suppl 2]:S1–S16

    PubMed  Google Scholar 

  8. DeVault KR, Castell DO, The Practice Parameters Committee of the American College of Gastroenterology (1999) Updated guidelines for the diagnosis and treatment of gastroenterol reflux disease. Am J Gastroenterol 94: 1434–1442

    Article  CAS  PubMed  Google Scholar 

  9. Hassan-Alin M, Andersson T, Bredberg E et al (2000) Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 56:665–670

    Article  CAS  PubMed  Google Scholar 

  10. Lind T, Rydberg L, Kyleback A et al (2000) Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 14:861–867

    Article  CAS  PubMed  Google Scholar 

  11. Röhss K, Hasselgren G, Hedenstrom H et al (2002) Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 47:954–958

    Article  PubMed  Google Scholar 

  12. Wilder-Smith C, Röhss K, Claar-Nilsson C et al (2002) Esomeprazole 40 mg provides faster and more effective acid control than lansoprazole 30 mg in patients with symptoms of gastroesophageal reflux disease (GERD). Gastroenterology 122(4)[Suppl 1]:A200

    Google Scholar 

  13. Wilder-Smith C, Röhss K, Lundin C et al (2000) Esomeprazole 40 mg provides more effective acid control than pantoprazole 40 mg. Gastroenterology 118:A22–A23

    Google Scholar 

  14. Röhss K, Wilder Smith C, Claar Nilsson C et al (2001) Esomeprazole 40 mg provides faster and more effective acid control than rabeprazole 20 mg in patients with symptoms of GERD. Am J Gastroenterol 96[Suppl S]:S45

    Google Scholar 

  15. Thomson ABR, Claar-Nilsson C et al (2000) Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg during single and repeated administration. Gut 47[Suppl III]:63

    Article  PubMed  Google Scholar 

  16. Wilder-Smith C, Röhss K, Claar Nilsson C (2000) Esomeprazole 40 mg provides more effective acid control than rabeprazole 20 mg. Gut 47[Suppl 3]:A63

    Article  Google Scholar 

  17. Wilder-Smith CH, Lind T, Lundin C et al (2003) Comparison of esomeprazole (20, 40, 80 mg) versus lansoprazole (15, 30 and 60 mg) on intragastric pH in healthy subjects. Gastroenterology 124:[4 Suppl]A44

    Article  Google Scholar 

  18. Janczewska I, Sagar M, Sjostedt S et al (1998) Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease. Scand J Gastroenterol 33:1239–1243

    Article  CAS  PubMed  Google Scholar 

  19. Robinson M, Maton PN, Rodriguez S et al (1997) Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 11:973–980

    Article  CAS  PubMed  Google Scholar 

  20. Tutuian R, Katz PO, Bochenek W et al (2002) Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers. Aliment Pharmacol Ther 16:829–836

    Article  CAS  PubMed  Google Scholar 

  21. Bell NJ, Hunt RH (1992) Progress with proton pump inhibition. Yale J Biol Med 65:649–657

    CAS  PubMed  Google Scholar 

  22. Holloway RH, Dent J, Narielvala F et al (1996) Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 38:649–654

    CAS  PubMed  Google Scholar 

  23. Kahrilas PJ, Falk GW, Johnson DA et al (2000) Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole study investigators. Aliment Pharmacol Ther 14:1249–1258

    Article  CAS  PubMed  Google Scholar 

  24. Richter JE, Kahrilas PJ, Johanson J et al (2001) Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 96:656–665

    Article  CAS  PubMed  Google Scholar 

  25. Castell DO, Kahrilas PJ, Richter JE et al (2002) Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis (EE). Am J Gastroenterol 97:575–583

    CAS  PubMed  Google Scholar 

  26. Lauritsen K, Deviere J, Bigard MA et al (2003) Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: metropole study results. Aliment Pharmacal Ther 17:333–341

    CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by a grant from AstraZeneca R&D Mölndal, Mölndal, Sweden.

Author information

Authors and Affiliations

  1. Experimental Medicine, Astrazeneca R&D Mölndal, Pepparedsleden 1, 431 83, Mölndal, Sweden

    Kerstin Röhss & Tore Lind

  2. Gastroenterology Group Practice, Berne, Switzerland

    Clive Wilder-Smith

Authors
  1. Kerstin Röhss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tore Lind
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Clive Wilder-Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kerstin Röhss.

Additional information

The experiments within this paper comply with the current laws of the countries in which they were conducted.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Röhss, K., Lind, T. & Wilder-Smith, C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 60, 531–539 (2004). https://doi.org/10.1007/s00228-004-0804-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-004-0804-6

Keywords

Search

Navigation